Educational supplement editorial for trendytones.org. This article summarizes published research. It is not medical advice. Melatonin supplements are not FDA-approved to treat, cure, or prevent diabetes or any other disease. Talk with your clinician before starting melatonin—especially if you use diabetes medicines, blood thinners, blood pressure drugs, or sedatives, or if you are pregnant or breastfeeding.
Introduction
Melatonin is best known as the body’s sleep hormone. Your pineal gland (a tiny gland in the brain) releases it mostly at night. That rise helps set your body clock—also called your circadian rhythm.
Many people take melatonin pills for jet lag or trouble falling asleep. Lately, some also wonder whether melatonin might help with blood sugar. That interest makes sense. Poor sleep and mixed-up sleep schedules are linked with a higher risk of type 2 diabetes.[1] And melatonin receptors sit on the cells that make insulin.
But here’s the honest headline: melatonin is still mainly a sleep aid. Any effect on blood sugar is secondary—and the research is mixed. Some studies look mildly helpful. Others show little change. A few even suggest melatonin can make glucose handling worse in certain situations, especially around meals or in people with a common gene variant.
This article walks through what the evidence shows, how melatonin might affect sugar metabolism, what doses trials used, how it compares with other approaches, and what to watch for safety-wise.
Effectiveness
Think of melatonin for blood sugar as uncertain, not proven.
What some pooled studies suggest
- One 2018 meta-analysis of randomized trials found lower fasting glucose (morning blood sugar after not eating) with melatonin, plus a small improvement in one insulin-sensitivity score. It did not find a clear drop in HbA1c—a lab test that reflects about three months of average blood sugar—or in HOMA-IR (a common insulin-resistance estimate).[2]
- A 2021 meta-analysis reported lower fasting glucose on average (about −4.7 mg/dL versus placebo).[3]
- Another 2021 analysis focused on insulin markers and reported lower insulin and HOMA-IR with melatonin.[4]
- A bedtime-focused 2021 meta-analysis found no clear change in fasting glucose or HbA1c, with only a small drop in fasting insulin.[5]
- A 2025 meta-analysis limited to type 2 diabetes reported a pooled HbA1c drop of about −0.65 percentage points, but no significant fasting-glucose change. Heterogeneity was very high, so that average is hard to trust for any one person.[6]
What individual trials remind us
Not every trial is positive:
- In adults with type 2 diabetes, 6 mg at bedtime for 8 weeks did not improve fasting glucose, HbA1c, or insulin-resistance markers versus placebo.[7]
- Prolonged-release 2 mg improved sleep over three weeks without short-term glucose changes. An HbA1c fall appeared later in an open extension—so that sugar finding is weaker than a true placebo-controlled result.[8]
- In men with type 2 diabetes, 10 mg nightly for three months reduced insulin sensitivity by about 12% on a careful clamp test—the gold-standard way to measure how well insulin works.[9]
Bottom line on effectiveness: Melatonin is not a blood-sugar treatment. Sleep benefits are better supported than glycemic benefits. If sugar markers move at all, effects look modest, inconsistent, and sometimes unfavorable. Never swap melatonin for diet, activity, or prescribed diabetes care.
Mechanism of Action
How could a sleep hormone touch blood sugar?
Night timing and insulin
Melatonin signals “nighttime” to many tissues. The pancreas—which makes insulin, the hormone that helps move sugar from blood into cells—has melatonin receptors (MT1 and MT2). In experimental and clinical work, melatonin signaling can dampen insulin release at times when the body expects sleep, not a big meal.[10][11]
That may be useful in a natural night-fasting pattern. It can be a problem if melatonin is high while you eat a carb-heavy meal.
The MTNR1B gene
A common variant in the MTNR1B gene (often discussed as rs10830963) is linked with higher fasting glucose, weaker early insulin release, and higher type 2 diabetes risk.[12][13] People who carry the risk version may be more sensitive to melatonin’s glucose-raising effect after a sugar load.[14] Extra melatonin signaling has even been framed as a diabetes risk pathway in detailed genetic and physiology work.[15]
What this means in plain English
Melatonin does not act like metformin or insulin. Any sugar effect is indirect—through body-clock timing, insulin release, and possibly insulin sensitivity. Reviews emphasize that timing, dose, meals, and genetics all matter, which helps explain why trial results disagree.[16]
Clinical Research Results
Acute studies (hours, not months)
In healthy women, 5 mg melatonin taken shortly before a glucose drink impaired glucose tolerance in both morning and evening tests.[17] Follow-up work found the hit was larger in carriers of the MTNR1B risk allele.[14]
Practical takeaway: melatonin near a meal—especially a high-carb meal—may not be ideal if glucose control is a concern.
Longer trials in diabetes
- Garfinkel et al.: Prolonged-release melatonin 2 mg helped sleep. Glucose markers were stable over three weeks; later HbA1c change came from a non-blinded extension.[8]
- Farrokhian et al.: Bedtime 6 mg for eight weeks did not support better glucose homeostasis versus placebo.[7]
- Lauritzen et al. (2022): Nightly 10 mg for three months lowered insulin sensitivity in men with type 2 diabetes.[9]
What systematic reviews conclude
Taken together, meta-analyses sometimes show small average improvements in fasting glucose or insulin markers,[2–4] while bedtime-focused pooling finds little HbA1c change,[5] and diabetes-focused pooling is mixed and highly variable.[6] High-quality physiology trials add an important caution: melatonin can impair glucose tolerance acutely and may reduce insulin sensitivity at higher nightly doses.[9][14][17]
So the research story is not “melatonin lowers blood sugar.” It is closer to “melatonin interacts with sugar metabolism in complex ways—sometimes helpful-looking on paper, sometimes not.”
Dosing
There is no established “blood sugar dose” of melatonin. Products are sold for sleep, not diabetes. What trials actually used:
| Setting | Typical amounts in research |
|---|---|
| Common sleep / diabetes trial range | About 2–10 mg at night, often for 3–12 weeks (sometimes longer)[5][6][8] |
| Garfinkel insomnia + diabetes | Prolonged-release 2 mg, ~2 hours before bed[8] |
| Farrokhian type 2 diabetes | 6 mg at bedtime for 8 weeks[7] |
| Lauritzen type 2 diabetes (clamp study) | 10 mg about 1 hour before bed for 3 months[9] |
| Acute glucose-tolerance studies | 5 mg shortly before a glucose challenge[17] |
Practical framing (not a prescription): Over-the-counter melatonin is often 1–5 mg. More is not automatically better for sleep—and higher doses appear more likely to nudge insulin sensitivity the wrong way in at least one careful diabetes trial.[9]
Timing tips grounded in the research:
- Take melatonin at night, close to bedtime—not in the morning.
- Avoid pairing it with a large carb meal when possible; acute data show worse glucose handling when melatonin and sugar arrive together.[17]
- If you have diabetes and try melatonin for sleep, plan glucose checks with your clinician rather than guessing.
Quality varies by brand. Prefer products that list the milligram dose clearly and, when possible, have third-party testing.
Comparable Efficacy to Other Similar Treatments
Head-to-head trials of melatonin versus other “blood sugar supplements” are rare. These comparisons are indirect—each topic has its own evidence base.
Sleep hygiene (non-pill first step). Short or poor sleep is linked with higher type 2 diabetes risk in large pooled observational research.[1] For many people, a steady sleep schedule, dark evenings, and less late-night eating may do more for metabolic health than adding a melatonin bottle—especially since melatonin’s glycemic evidence is shaky.
Chromium. Meta-analyses in type 2 diabetes sometimes show modest average drops in fasting glucose or HbA1c, but careful reviews also judge the clinical benefit as limited and inconsistent.[18][19] Chromium is marketed for glucose; melatonin is not primarily a glucose supplement. Neither replaces medical therapy.
Berberine. A meta-analysis of randomized trials reported glycemic and lipid improvements in type 2 diabetes contexts, though study quality was often low.[20] Many evidence summaries discuss berberine’s glucose signal more consistently than melatonin’s—still with quality limits.
Honest comparative takeaway: If the goal is sleep, melatonin has a clearer use case than chromium or berberine. If the goal is blood sugar, sleep habits, nutrition, activity, and proven medicines sit far above melatonin. Among supplements, melatonin is not a standout glycemic option based on current mixed data.[2–9]
Safety Profile
Adverse Effects
Short-term melatonin is usually well tolerated. Common effects include daytime sleepiness, headache, dizziness, and nausea.[21] Vivid dreams or feeling “groggy” the next morning also show up in everyday use.
Serious harm appears uncommon at typical short-term doses, but long-term safety data are thinner than for short courses.[21]
Metabolic caution: because melatonin can impair glucose tolerance acutely and reduced insulin sensitivity in a 10 mg diabetes trial, people with diabetes should not assume “natural equals harmless for sugar.”[9][17]
Drug Interactions
High-quality interaction trials are limited. Practical cautions supported by clinical references and physiology:
- Diabetes medicines (insulin, sulfonylureas, and others): Effects on glucose can go either way in the literature. Monitor glucose if melatonin is added; do not adjust diabetes drugs on your own.
- Sedatives, alcohol, and other sleep drugs: Melatonin can add to drowsiness.
- Blood thinners (for example, warfarin): Melatonin may increase bleeding risk in some reports; check with a clinician or pharmacist.
- Blood pressure medicines and other CNS-active drugs: Individual advice is safest; melatonin can cause next-day fogginess that interacts poorly with some regimens.
- CYP1A2 inhibitors (such as fluvoxamine): These can raise melatonin levels substantially; combinations may need avoidance or specialist guidance.
Precautions
- Not a diabetes treatment. Melatonin is not FDA-approved to treat high blood sugar.
- Pregnancy and breastfeeding. Human safety data for supplemental melatonin are insufficient for routine use; avoid unless your clinician says otherwise.
- Autoimmune disease. Melatonin can influence immune signaling in experimental settings; people with autoimmune conditions should ask a clinician before regular use.
- Older adults / dementia. Extra caution—daytime sedation risk can be higher; professional guidance is important.
- Surgery or medication changes. Tell your care team about any melatonin use.
- Gene curiosity. MTNR1B testing is not a routine consumer recommendation for deciding on melatonin; the research mainly explains why responses differ.
FAQs
Q1. Can melatonin reverse type 2 diabetes?
No. At best, some reviews show small average shifts in glucose or insulin markers.[2–4] Diabetes care still rests on lifestyle, monitoring, and proven medicines.
Q2. If melatonin helps my sleep, will my blood sugar automatically improve?
Better sleep may help overall health, and poor sleep is linked with higher diabetes risk.[1] But melatonin itself does not reliably improve HbA1c or fasting glucose in every trial.[5][7][9]
Q3. Is night dosing safer for blood sugar than daytime dosing?
Night dosing matches melatonin’s natural pattern and is how most trials are run. Daytime melatonin can leave you sleepy and may interfere with daytime glucose handling.[17] Still, even evening melatonin taken near a glucose load can worsen tolerance in short experiments.[17]
Q4. I take metformin (or insulin). Can I add melatonin for sleep?
Ask your clinician first. Melatonin’s glucose effects are unpredictable. Plan monitoring rather than assuming a free pass.[7][9]
Q5. Does the MTNR1B gene mean I should avoid melatonin?
Carriers of a common risk variant may be more prone to melatonin-related glucose impairment after meals.[14][15] That does not mean every carrier must avoid melatonin for sleep—but it does mean meal timing and medical advice matter more.
Q6. What if my main goal is blood sugar, not sleep?
Focus on eating patterns, activity, weight management when appropriate, sleep schedule, and prescribed therapy. Melatonin is a weak and uncertain tool for glucose control compared with those foundations.[2–9][16]
Conclusion
Melatonin’s job in the body is to mark night and support sleep timing. Links to insulin and glucose are real in biology—and still messy in clinical practice.
Some meta-analyses hint at small improvements in fasting glucose or insulin-resistance markers.[2–4] Other pools find little HbA1c change.[5] Careful trials show no benefit at 6 mg in one diabetes study and worse insulin sensitivity at 10 mg in another.[7][9] Acute studies warn against melatonin close to sugar loads, especially in people with certain MTNR1B variants.[14][17]
If melatonin has a place for you, the evidence-aligned posture is:
- Use it mainly for sleep timing, not as a diabetes supplement.
- Prefer modest night doses in the range actually studied for sleep (often 1–5 mg; some trials used up to 10 mg).[8][9]
- Keep it away from large carb meals when possible.[17]
- Monitor glucose if you have diabetes or take glucose-lowering drugs.[7][9]
- Keep expectations honest: sleep hygiene and standard diabetes care remain the main story.
Melatonin can be a helpful footnote for sleep. For blood sugar, it should not be the headline.
References
- Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33(2):414-420. PMID: 19910503.
- Doosti-Irani A, Ostadmohammadi V, Mirhosseini N, et al. The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2018;50(11):783-790. PMID: 30396207.
- Delpino FM, Figueiredo LM, Nunes BP. Effects of melatonin supplementation on diabetes: A systematic review and meta-analysis of randomized clinical trials. Clin Nutr. 2021;40(7):4595-4605. PMID: 34229264.
- Li Y, Xu Z. Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2021;53(9):616-624. PMID: 34496412.
- Lauritzen ES, Kampmann U, Smedegaard SB, Støy J. Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021;95(5):691-701. PMID: 34370338.
- Lv X, Sun H, Ai S, Zhang D, Lu H. The effect of melatonin supplementation on glycemic control in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2025;16:1572613. PMID: 40698248.
- Farrokhian A, Tohidi M, Ahanchi NS, et al. Effect of Bedtime Melatonin Administration in Patients with Type 2 Diabetes: A Triple-Blind, Placebo-Controlled, Randomized Trial. Iran J Pharm Res. 2019;18(Suppl1):258-268. PMID: 32802105.
- Garfinkel D, Zorin M, Wainstein J, et al. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307-313. PMID: 21887103.
- Lauritzen ES, Kampmann U, Pedersen MGB, et al. Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes—A randomized placebo-controlled crossover trial. J Pineal Res. 2022;73(1):e12809. PMID: 35619221.
- Peschke E, Bähr I, Mühlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(4):6981-7015. PMID: 23535335.
- Peschke E, Bähr I, Mühlbauer E. Experimental and clinical aspects of melatonin and clock genes in diabetes. J Pineal Res. 2015;59(1):1-23. PMID: 25904189.
- Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82-88. PMID: 19060908.
- Sparsø T, Bonnefond A, Andersson E, et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes. 2009;58(6):1450-1456. PMID: 19324940.
- Garaulet M, Gómez-Abellán P, Rubio-Sastre P, et al. Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans. Metabolism. 2015;64(12):1650-1657. PMID: 26440713.
- Tuomi T, Nagorny CLF, Singh P, et al. Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. Cell Metab. 2016;23(6):1067-1077. PMID: 27185156.
- Garaulet M, Qian J, Florez JC, et al. Melatonin Effects on Glucose Metabolism: Time To Unlock the Controversy. Trends Endocrinol Metab. 2020;31(3):192-204. PMID: 31901302.
- Rubio-Sastre P, Scheer FA, Gómez-Abellán P, Madrid JA, Garaulet M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014;37(10):1715-1719. PMID: 25197811.
- Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care. 2007;30(8):2154-2163. PMID: 17519436.
- Costello RB, Dwyer JT, Bailey RL. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutr Rev. 2016;74(7):455-468. PMID: 27261273.
- Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654. PMID: 23118793.
- Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ. 2006;332(7538):385-393. PMID: 16473858.